Showing Results for: “diabetes exercise”

James Wrobel, DPM, MS, has been selected to receive the American Diabetes Association’s® (ADA’s) 2019 Roger Pecoraro Award. This award recognizes a researcher who has made significant scientific contributions and demonstrates an untiring commitment to improving the understanding of the detection, treatment, and prevention of diabetic foot complications. Dr. Wrobel will be recognized with this honor during the ADA’s 79th Scientific Sessions, June 7-11, 2019, at the Moscone Convention Center in San Francisco. He will deliver the Roger Pecoraro Award Lecture, “ Artificial Intelligence for

Prevalence of diabetes disproportionately impacted lower-income populations; highlights the need for increased prevention strategies A new study from researchers at the Centers for Disease Control and Prevention (CDC) reveal income-related inequalities (IRI) in rates of diabetes exist between 2001 and 2018. The findings were presented at the virtual 81st Scientific Sessions held by the American Diabetes Association ® (ADA). Throughout the U.S., diabetes prevalence has increased over the past two decades, disproportionately affecting low-income populations. For example, between 2011 and 2014

The U.S. Food and Drug Administration (FDA) convened the Endocrinologic and Metabolic Drugs Advisory Committee Meeting (EMDAC) on May 27, 2021, to review Teplizumab, which has shown the ability to delay the onset of Type 1 diabetes symptoms by two years. The American Diabetes Association ® (ADA) applauds the FDA Advisory Committee’s approval of Teplizumab for those at risk for developing type 1 diabetes (T1D). Click here to view the official comments submitted by the ADA. In response, Dr. Robert Gabbay, Chief Scientific and Medical Officer for the ADA shared the following: “This is undoubtedly

Bipartisan King-Murkowski bill allocates testing resources for communities most at-risk The American Diabetes Association® (ADA), the nation’s leading organization for all people living with diabetes, announced its strong support for the COVID-19 Testing, Reaching, And Contacting Everyone (TRACE) Act in a letter to Senators Angus King (I-ME) and Lisa Murkowski (R-AK), who introduced the bill. The ADA also called on all Members of Congress to support this important legislation. The bill ensures that local organizations get the resources they need to mobilize testing and contact tracing efforts

In Wisconsin, the ADA’s “friend of the court” brief urges changes be made to give those with diabetes and other chronic conditions safer access to vote On Monday, The American Diabetes Association® (ADA) filed an amicus curiae, or “friend of the court” brief in the federal court case Edwards et al. v. Vos et al. in the U.S. District Court for the Western District of Wisconsin, alleging that key changes are needed to enable people with diabetes and other chronic diseases to vote safely in this year’s elections. Proceeding without these changes would violate the U.S. Constitution and the

Latest CDC and NIDDK sponsored SEARCH for Diabetes in Youth research indicates substantial percentage of today’s youth with diabetes are not meeting recommended A1C goals Despite the increased availability of diabetes technology, new therapies and more aggressive glycemic targets, today’s youth and young adults with diabetes in the United States are not demonstrating improved glycemic control compared to their counterparts from years past. Most notably, many age groups have worse glycemic control compared to youth and young adults from 2002-2007. Researchers revealed these data today at the

Results of NIDDK’s, Fuzzy Logic Automated Insulin Regulation (FLAIR) study showed increased time in range and improved A1C levels in adolescents and young adults who used system Medtronic’s Advanced Hybrid Closed-Loop system use in adolescents and young adults with type 1 diabetes (T1D) can lead to improved daytime blood sugar control without an increase in hypoglycemia, according to research presented today at the American Diabetes Association’s® (ADA’s) 80th Scientific Sessions. The presentation, “FLAIR—An NIDDK-Sponsored International, Multi-site Randomized Crossover Trial of AHCL vs. 670G

Today, the California Assembly Health Committee passed Assembly Bill 2203 (Nazarian), legislation that will cap insulin co-pays at $50 per 30-day supply of insulin and total out-of-pocket costs for insulin at $100 for those in state-regulated health insurance plans. The legislation also authorizes the California Attorney General to investigate the rising price of insulin in the state. The American Diabetes Association (ADA) is sponsoring the legislation along with the Health Trust. “The American Diabetes Association is appreciative of the support of our bill author Assemblymember Adrin

Today, the U.S. Food & Drug Administration (FDA) officially moved insulin to the biologic regulatory framework. All insulins on the market have officially been deemed biologics by the FDA—paving the way for biosimilar and interchangeable insulins. Learn more about what this change means for people living with diabetes at diabetes.org/biologics . LaShawn McIver, MD, MPH, Senior Vice President of Government Affairs & Advocacy for the American Diabetes Association (ADA), issued the following statement: "Insulin is life-sustaining for about seven million Americans—too many of whom can’t afford it

The American Diabetes Association (ADA) announces this year’s National Scientific and Health Care Achievement Award recipients The American Diabetes Association ® (ADA) is proud to announce the recipients of the 2020 National Scientific and Health Care Achievement Awards. The awards recognize academics, health care providers and educators who have contributed to tangible advances in the field of diabetes care and research. Each recipient has shown outstanding commitment to achieving the vision of the ADA: life free of diabetes and all its burdens. “I am thrilled to recognize the eight talented